{
  "id": "5c73ad077c78d69471000090",
  "type": "factoid",
  "question": "Safinamide is approved for treatment of which disease?",
  "ideal_answer": "Safinamide is a monoamine-oxidase B (MAO-B) inhibitor licensed as add-on therapy for people with idiopathic Parkinson's disease who are experiencing motor fluctuations with levodopa.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/29760163",
    "http://www.ncbi.nlm.nih.gov/pubmed/29670409",
    "http://www.ncbi.nlm.nih.gov/pubmed/29339106",
    "http://www.ncbi.nlm.nih.gov/pubmed/30271159",
    "http://www.ncbi.nlm.nih.gov/pubmed/30142650",
    "http://www.ncbi.nlm.nih.gov/pubmed/27802242",
    "http://www.ncbi.nlm.nih.gov/pubmed/30291173",
    "http://www.ncbi.nlm.nih.gov/pubmed/29441484",
    "http://www.ncbi.nlm.nih.gov/pubmed/29167350",
    "http://www.ncbi.nlm.nih.gov/pubmed/25851099",
    "http://www.ncbi.nlm.nih.gov/pubmed/28110399",
    "http://www.ncbi.nlm.nih.gov/pubmed/26587996"
  ],
  "snippets": [
    {
      "text": "Safinamide has been recently approved as an add-on to levodopa therapy for Parkinson disease. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29167350",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " These data are consistent with the anticonvulsant and antiparkinsonian actions of safinamide and provide support for the nondopaminergic mechanism of its action.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29167350",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Safinamide: a new hope for Parkinson's disease?",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29339106",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "The loss of dopaminergic neurons (DAn) and reduced dopamine (DA) production underlies the reasoning behind the gold standard treatment for Parkinson's disease (PD) using levodopa (L-DOPA). Recently licensed by the European Medicine Agency (EMA) and US Food and Drug Administration (FDA), safinamide [a monoamine oxidase B (MOA-B) inhibitor] is an alternative to L-DOPA; as we discuss here, it enhances dopaminergic transmission with decreased secondary effects compared with L-DOPA. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29339106",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Overall, safinamide can be considered to have potential antidyskinetic and neuroprotective effects and future trials and/or studies should be performed to provide further evidence for its potential as an anti-PD drug.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29339106",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Real life evaluation of safinamide effectiveness in Parkinson's disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29441484",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "In this retrospective study, we evaluated both efficacy and effectiveness of safinamide 50 and 100\u00a0mg in the treatment of motor fluctuations and disabling dyskinesias in a cohort of patients with idiopathic Parkinson's disease (PD). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29441484",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In conclusion, safinamide is safe and effective in improving motor complications in patients with idiopathic PD and can be considered a useful levodopa sparing strategy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29441484",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Safinamide: an add-on treatment for managing Parkinson's disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29670409",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Safinamide (Xadago - Zambon S.p.A) is a monoamine-oxidase B (MAO-B) inhibitor licensed as add-on therapy for people with idiopathic Parkinson's disease who are experiencing motor fluctuations with levodopa.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29760163",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In the EU, safinamide is approved for the treatment of mid- to late-stage fluctuating Parkinson's disease (PD) as add-on therapy to a stable dose of levodopa alone or in combination with other PD medications.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28110399",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "AIM\nSafinamide (Xadago\u00ae) is a newly approved selective MAO-B inhibitor for the treatment of Parkinson's Disease (PD).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30142650",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Safinamide is a\u00a0new drug with dopaminergic and non-dopaminergic properties, approved in Europe as adjunct therapy to levodopa for the treatment of fluctuating PD patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27802242",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Safinamide (Xadago\u00ae) is a novel medication with both dopaminergic and non-dopaminergic effects, approved first by the European Commission and more recently by the US Food and Drug Administration (FDA) as an adjunctive treatment to carbidopa/levodopa in patients with mid- to late-stage Parkinson's disease (PD) and motor fluctuations.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30271159",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Safinamide (Xadago) is a novel dual-mechanism drug that has been approved in the European Union and United States as add-on treatment to levodopa in Parkinson's disease therapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30291173",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Safinamide has been recently approved as an add-on to levodopa therapy for Parkinson disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29167350",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Safinamide is approved in the EU, Iceland, Lichtenstein and Norway, as an add-on therapy to stable-dose levodopa, alone or in combination with other PD therapies in mid- to late-stage fluctuating PD patients; regulatory submissions have also been filed in the USA and Switzerland for its use in this indication.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25851099",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In 2014, safinamide was approved in the European Economic Area, as \"an add-on therapy to stable dose levodopa, alone or in combination with other PD therapies in mid- to late-stage-fluctuating PD patients.\"",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26587996",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In the EU, safinamide is approved for the treatment of mid- to late-stage fluctuating Parkinson's disease (PD) as add-on therapy to a stable dose of levodopa alone or in combination with other PD medications. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28110399",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "is a novel medication with both dopaminergic and non-dopaminergic effects, approved first by the European Commission and more recently by the US Food and Drug Administration (FDA) as an adjunctive treatment to carbidopa/levodopa in patients with mid- to late-stage Parkinson's disease (PD) and motor fluctuations. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30271159",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In 2014, safinamide was approved in the European Economic Area, as an add-on therapy to stable dose levodopa, alone or in combination with other PD therapies in mid- to late-stage-fluctuating PD patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26587996",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Safinamide is a\u00a0new drug with dopaminergic and non-dopaminergic properties, approved in Europe as adjunct therapy to levodopa for the treatment of fluctuating PD patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27802242",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Parkinson's disease"
}